Compare 10X Genomics Inc (TXG) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Wynn Resorts, Limited — how do they compare? 10X Genomics Inc trades at $67.59 (market cap $8.55B), while Wynn Resorts, Limited trades at $90.11 (market cap $9.50B). The key difference: 10X Genomics Inc and Wynn Resorts, Limited are close in size by market cap, and Wynn Resorts, Limited pays a 1.08% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| TXG | WYNN | |
|---|---|---|
Market Cap | $8.55B | $9.50B |
Sector | Health | Consumer Cyclical |
52-Week High | $67.29 | $133.34 |
52-Week Low | $11.34 | $90.23 |
Enterprise Value | $8.08B | $19.74B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TXG trades at $65.60, up 4.71% today, with a bullish technical signal and recent earnings beats. The stock shows improving fundamentals, with 2025 revenue at $642.82M and net loss narrowing to -$43.54M. Positive sentiment is driven by patent wins, Atera platform demand, and institutional interest, though valuation metrics like P/S of 13.58 and EV/EBITDA of 142.2 remain elevated.
Outlook is cautiously optimistic with upside potential from Atera execution, but risks include high valuation, persistent losses, and competitive pressures. Analyst consensus is mixed with a $50.56 price target below current levels, indicating near-term caution despite long-term growth prospects in genomics.
Wynn Resorts (WYNN) trades at $92.22, up 0.74% today, with a bearish technical signal and mixed earnings. Q2 2026 EPS beat estimates at $1.24, but Q4 2025 and Q1 2026 missed. Revenue reached $7.14B in 2025, with net income margin at 6.06%. Recent news highlights Macau strength offset by U.S. margin pressure and rising capital expenditures for new projects.
Outlook: Analyst consensus is bullish with a $132.44 price target, but risks include high debt ($10.5B long-term), profit margin compression, and significant capital spending. The stock offers growth potential from Macau recovery and new developments, yet faces headwinds from operational costs and leverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
